Egrifta (Tesamorelin) Medicare Part D Coverage: Costs, Alternatives, and How to Save

What Tesamorelin Is and Why Coverage Matters

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that the FDA approved in 2010 specifically for reducing visceral adipose tissue in adults with HIV-associated lipodystrophy. The drug stimulates pulsatile growth hormone secretion from the anterior pituitary, which in turn increases lipolysis of visceral fat stores. A 26-week key trial (N=412) showed tesamorelin reduced trunk fat by 15.2% versus 5.0% with placebo, measured by CT scan (Falutz et al., JAMA 2007). The phase 3 confirmatory trial demonstrated sustained visceral fat reduction of approximately 18% at 52 weeks among treatment completers (Falutz et al., J Acquir Immune Defic Syndr 2010).

Coverage matters because the brand-name list price runs approximately $3,500 per month. For Medicare beneficiaries living on fixed incomes, that figure is prohibitive without insurance support. The narrow FDA label creates a formulary gatekeeping problem: plans that cover the drug impose strict utilization management, and plans that do not list it force patients into appeals or alternative sourcing. Understanding the specific Part D field for Egrifta in 2026 can save a patient thousands of dollars annually.

How Medicare Part D Formularies Handle Egrifta

Medicare Part D plans organize drugs into formulary tiers, and Egrifta consistently lands on Specialty Tier 5 (when included at all). The Centers for Medicare & Medicaid Services (CMS) define specialty tier drugs as those exceeding a cost threshold of $830 per month in 2026. Brand Egrifta SV exceeds that threshold by more than four times.

Plans on the CMS formulary finder that list Egrifta typically require three conditions: a confirmed HIV diagnosis, documented lipodystrophy with imaging evidence (CT or DEXA showing visceral adiposity), and failure or contraindication to lifestyle intervention. The Medicare Part D Prescription Drug Benefit Manual (Chapter 6) permits plans to impose step therapy and prior authorization for specialty drugs, and virtually all plans exercise both options for tesamorelin.

Beneficiaries enrolled in Medicare Advantage Prescription Drug (MA-PD) plans face similar restrictions. A 2023 analysis of MA-PD formularies found that fewer than 35% of plans included any GHRH analogue on formulary, with the remainder requiring exception requests (KFF Medicare Part D analysis). Patients denied at the initial coverage determination have the right to a standard appeal within 7 days or an expedited appeal within 72 hours under 42 CFR § 423.590.

The Real Out-of-Pocket Cost Under Part D

The 2026 Part D benefit design, shaped by the Inflation Reduction Act (IRA), caps annual true out-of-pocket (TrOOP) spending at $2,000 for all covered Part D drugs. This redesign eliminated the coverage gap ("donut hole") and introduced a manufacturer discount program in the catastrophic phase.

Here is how costs break down for a beneficiary whose plan covers Egrifta at Specialty Tier coinsurance of 25%:

The annual deductible for Part D in 2026 is $590. After the deductible, a 25% coinsurance on a $3,500 monthly drug yields $875 per month in patient cost during the initial coverage phase. The beneficiary reaches the $2,000 TrOOP cap after roughly two months of fills. From that point forward, the plan and manufacturer discount cover remaining costs for the rest of the calendar year.

Before the IRA cap, a Part D enrollee could face $8,000 or more in annual out-of-pocket costs for Egrifta. The $2,000 hard cap represents a significant structural improvement. The CMS 2026 Part D benefit parameters announcement confirmed these thresholds. Beneficiaries should verify their specific plan's coinsurance rate at Medicare.gov Plan Finder.

Prior Authorization: What Prescribers Need to Submit

Nearly every Part D plan that covers Egrifta requires prior authorization (PA). The PA process for tesamorelin is more documentation-intensive than for most specialty drugs because of the narrow FDA label.

Standard documentation includes: confirmed HIV-1 infection on stable antiretroviral therapy (ART), body composition imaging (CT scan at L4-L5 or whole-body DEXA) showing excess visceral adipose tissue, trial of diet and exercise intervention for at least 3 months, and documentation that the lipodystrophy causes functional impairment or metabolic complications. The FDA-approved prescribing information for Egrifta SV specifies the indication as reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and payers anchor their PA criteria to this language.

Plans typically issue an initial approval for 6 months, then require reauthorization with repeat imaging showing sustained or continued visceral fat reduction. If the prescriber cannot demonstrate at least a 10% reduction in visceral fat on follow-up CT, many plans deny continuation. A 2024 retrospective of PA outcomes for injectable specialty drugs found that initial denial rates for GHRH analogues exceeded 40%, though approximately 60% of denials were overturned on first-level appeal (AMCP analysis of specialty drug PA trends).

Off-Label Use and Coverage Denials

Interest in tesamorelin extends well beyond HIV-associated lipodystrophy. Research has explored its effects on hepatic fat reduction, cognitive function in aging, and body composition in non-HIV populations. A randomized controlled trial (N=31) showed tesamorelin reduced hepatic fat fraction by 37% in HIV-positive adults with nonalcoholic fatty liver disease (Stanley et al., Lancet HIV 2014). Separate work found that GHRH analogue administration improved executive function and verbal memory in healthy older adults and those with mild cognitive impairment (Baker et al., Arch Neurol 2012).

These off-label applications are the primary reason non-HIV patients seek tesamorelin prescriptions. Medicare Part D, however, has no obligation to cover off-label use unless the indication is supported by an accepted compendium (such as the American Hospital Formulary Service Drug Information compendium) or peer-reviewed literature meeting CMS standards. In practice, off-label tesamorelin claims are denied at exceedingly high rates under Part D. The Medicare Benefit Policy Manual, Chapter 15, Section 50.4.2 outlines the conditions under which off-label drug use may be covered, but GHRH analogues for non-HIV indications have not met this bar as of 2026.

Patients seeking tesamorelin for anti-aging, body composition, or cognitive purposes should expect to pay entirely out of pocket unless they have a qualifying HIV diagnosis with documented lipodystrophy.

Manufacturer Assistance and Copay Programs

Theratechnologies operates the Egrifta SV patient support program, which provides two pathways for cost reduction. The first is a copay assistance card for commercially insured patients. This card can reduce out-of-pocket costs to as low as $0 per month for eligible patients with private insurance. The program terms, including annual caps, are available through the Theratechnologies Egrifta SV support portal.

The second pathway is a patient assistance program (PAP) for uninsured or underinsured patients. Eligibility is typically based on household income at or below 400% of the federal poverty level (FPL). The 2026 FPL for a single-person household is $15,650, making the 400% threshold $62,600. Qualifying patients may receive Egrifta SV at no cost directly from the manufacturer.

There is an important limitation for Medicare beneficiaries: federal anti-kickback statute prohibitions prevent Medicare patients from using manufacturer copay cards. The OIG guidance on manufacturer copay coupons explicitly states that offering or receiving remuneration to induce the purchase of federally reimbursed drugs may violate the Anti-Kickback Statute. Medicare patients must instead rely on independent charitable foundations or the Theratechnologies PAP (if they meet income criteria).

Independent copay assistance foundations such as the Patient Access Network Foundation (PAN), the HealthWell Foundation, and the Patient Advocate Foundation periodically open funds for injectable specialty drugs. Availability fluctuates quarterly, and funds deplete quickly. Patients should check panfoundation.org and healthwellfoundation.org regularly.

Compounded Tesamorelin: A Lower-Cost Alternative

Compounded tesamorelin has become the most common cost-reduction strategy for patients who cannot obtain or afford brand Egrifta. Compounding pharmacies registered under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act can produce tesamorelin using bulk active pharmaceutical ingredient (API) when certain conditions are met.

Average pricing for compounded tesamorelin runs approximately $350 per month, representing a roughly 90% cost reduction from the brand product. This price point places it within reach for most patients paying out of pocket, including Medicare beneficiaries whose plans do not cover brand Egrifta. The FDA's compounding quality page describes oversight expectations for 503B outsourcing facilities, which must comply with current good manufacturing practice (cGMP) standards.

Key considerations when sourcing compounded tesamorelin include verifying that the pharmacy holds a valid state license, confirming 503B registration status through the FDA outsourcing facility database, requesting a certificate of analysis (COA) for each batch, and confirming the peptide purity exceeds 98% by HPLC. Compounded products are not FDA-approved, do not carry the same regulatory assurances as brand Egrifta SV, and are not typically covered by Medicare Part D.

The FDA draft guidance on compounding from bulk substances should be monitored for any changes to the regulatory status of compounded peptides, as this field continues to evolve in 2026.

Medicare Extra Help (Low-Income Subsidy)

Beneficiaries with limited income and resources may qualify for the Medicare Extra Help program (also called the Low-Income Subsidy, or LIS). Extra Help can pay for most of the Part D premium, deductible, and coinsurance, reducing costs for covered drugs to $0, $11.20 per prescription in 2026.

Eligibility thresholds for full Extra Help in 2026 are: annual income below 150% FPL ($23,475 for an individual) and countable resources below $17,220 for an individual. Partial Extra Help extends to higher income brackets with sliding-scale cost sharing. The Social Security Administration Extra Help page provides the application form and current thresholds.

If a patient's Part D plan covers Egrifta and the patient qualifies for Extra Help, the coinsurance that would otherwise be $875 per month at Specialty Tier rates drops to a nominal copay. This makes LIS one of the most impactful cost-reduction programs available, though it applies only when the plan actually lists tesamorelin on formulary.

State Pharmaceutical Assistance Programs (SPAPs) in certain states provide additional coverage layers. The Medicare.gov SPAP finder can identify state-specific programs. The AIDS Drug Assistance Program (ADAP), funded under the Ryan White HIV/AIDS Program through HRSA, may cover Egrifta for qualifying HIV-positive individuals in states where ADAP formularies include GHRH analogues.

Step-by-Step Strategy to Minimize Egrifta Costs on Medicare

The most effective approach combines multiple strategies in sequence. Start by confirming your Part D plan's formulary status for Egrifta SV using the Medicare Plan Finder. If the drug is listed, have your prescriber submit prior authorization with all required documentation (HIV confirmation, imaging, ART regimen, lifestyle intervention records).

If PA is approved, the IRA's $2,000 annual TrOOP cap limits your exposure. Apply for Extra Help through SSA if income-eligible. Check independent foundations (PAN, HealthWell) for open specialty drug funds.

If PA is denied, file a standard appeal within 60 days. Include peer-reviewed evidence supporting the medical necessity of tesamorelin for your specific clinical scenario. The Medicare Beneficiary Ombudsman can assist with navigating the appeals process.

If coverage is unavailable or the appeal fails, evaluate compounded tesamorelin from a 503B-registered pharmacy as an out-of-pocket alternative at approximately $350/month. This route bypasses insurance entirely. Also consider annual open enrollment (October 15 through December 7) to switch to a Part D plan that does include Egrifta on formulary for the following year, using Medicare Plan Finder to compare options.

Comparing Egrifta SV to Other GH-Axis Therapies Under Part D

Tesamorelin is not the only drug acting on the growth hormone axis, but it is the only GHRH analogue with FDA approval for lipodystrophy. Recombinant human growth hormone (somatropin) products such as Norditropin, Genotropin, and Humatrope have broader indications including adult growth hormone deficiency (AGHD), and some Part D plans cover somatropin more readily than tesamorelin for patients who also meet AACE/ACE guidelines for GH replacement.

Somatropin directly replaces growth hormone rather than stimulating its endogenous release. The clinical distinction matters: tesamorelin preserves the pulsatile GH secretion pattern and feedback regulation, which may reduce the risk of supraphysiologic IGF-1 levels. A comparative analysis showed that tesamorelin-treated patients maintained IGF-1 within the normal range more consistently than somatropin-treated patients (Dhillon et al., Drugs 2011). The Endocrine Society Clinical Practice Guideline on GH replacement provides the standard-of-care framework for GH-axis therapy selection.

For patients specifically seeking visceral fat reduction in the context of HIV, tesamorelin remains the only evidence-based pharmacotherapy with a dedicated Phase 3 program supporting this indication.

What Changes to Watch in 2026 and Beyond

The Medicare Drug Price Negotiation Program, authorized under the IRA, is expanding its list of negotiated drugs annually. While Egrifta SV has not appeared on the negotiation list for 2026, future inclusion remains possible for high-cost specialty drugs. The CMS IRA implementation page tracks the negotiation timeline and drug selections.

Biosimilar and follow-on peptide development could also alter the pricing field. Tesamorelin's composition patent has been subject to challenge, and any successful generic or follow-on product would likely reduce both brand and compounded pricing. The FDA Orange Book lists patent and exclusivity information for Egrifta SV.

Beneficiaries currently paying $3,500/month cash or navigating complex PA processes should reassess their coverage options at every annual enrollment period and verify program eligibility quarterly, as fund availability and formulary placements shift frequently.

The $2,000 annual TrOOP cap under the IRA remains the single most protective provision for Medicare Part D beneficiaries prescribed high-cost specialty drugs like Egrifta SV in 2026.